Top

International Journal of Clinical Oncology

Published in:

01-12-2013 | Original Article

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer

Authors: Ryota Nakanishi, Jun Harada, Munkhbold Tuul, Yan Zhao, Koji Ando, Hiroshi Saeki, Eiji Oki, Takefumi Ohga, Hiroyuki Kitao, Yoshihiro Kakeji, Yoshihiko Maehara

Published in: International Journal of Clinical Oncology | Issue 6/2013

Abstract

Background

Mutations of the KRAS or BRAF genes are now recognized as prognostic markers for colorectal cancer (CRC). They are also important predictive markers for resistance to the monoclonal antibodies that target the epidermal growth factor receptor.

Methods

In this retrospective study, KRAS and BRAF mutations were analyzed using a direct sequence method in 254 Japanese CRC patients, and the associations between KRAS or BRAF mutations and clinicopathological characteristics or outcome were evaluated.

Results

KRAS and BRAF mutations were detected in 33.5 and 6.7 % of all patients, respectively. Consistent with previous reports, BRAF mutations were significantly correlated with the anatomical site of the tumor (P < 0.001), tumor grade (P = 0.001) and high frequency of microsatellite instability (P < 0.001). BRAF mutations were correlated with poor overall survival in the full patient cohort (P = 0.009). KRAS mutations were significantly correlated with poor recurrence-free survival (P = 0.03), particularly in patients with stage II CRC (P = 0.007). Cox regression analysis showed that KRAS mutations were a negative predictor of recurrence-free survival in patients with stage II CRC.

Conclusion

KRAS mutation status could be a novel biomarker for predicting disease recurrence in Japanese patients with stage II CRC.

Takachi R, Tsubono Y, Baba K et al (2011) Red meat intake may increase the risk of colon cancer in Japanese, a population with relatively low red meat consumption. Asia Pac J Clin Nutr 20:603–612PubMed

Suzuki K, Muto T, Sawada T (1995) Prevention of local recurrence by extended lymphadenectomy for rectal cancer. Surg Today 25:795–801PubMedCrossRef

Kobayashi H, Mochizuki H, Kato T et al (2011) Lymph node ratio is a powerful prognostic index in patients with stage III distal rectal cancer: a Japanese multicenter study. Int J Colorectal Dis 26:891–896PubMedCrossRef

De Roock W, De Vriendt V, Normanno N et al (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594–603PubMedCrossRef

Sylvester BE, Huo D, Khramtsov A et al (2012) Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 18:350–359

Uehara K, Ishiguro S, Hiramatsu K et al (2011) Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer. Jpn J Clin Oncol 41:1229–1232PubMedCrossRef

Moosmann N, von Weikersthal LF, Vehling-Kaiser U et al (2011) Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. J Clin Oncol 29:1050–1058PubMedCrossRef

Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361:2449–2460PubMedCentralPubMedCrossRef

Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019PubMedCrossRef

10.

Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261PubMedCrossRef

11.

Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487PubMedCrossRef

12.

Weisenberger DJ, Siegmund KD, Campan M et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787–793PubMedCrossRef

13.

Yokota T, Ura T, Shibata N et al (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856–862PubMedCentralPubMedCrossRef

14.

Jass JR, Sobin LH (1989) Histological typing of intestinal tumours. WHO international histological classification of tumours no. 15, 2nd edn. Springer, Berlin

15.

Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York

16.

Zhao Y, Miyashita K, Ando T et al (2008) Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1. Gene 423:188–193PubMedCrossRef

17.

Oda S, Oki E, Maehara Y, Sugimachi K (1997) Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. Nucleic Acids Res 25:3415–3420PubMedCentralPubMedCrossRef

18.

Vilar E, Gruber SB (2010) Microsatellite instability in colorectal cancer––the stable evidence. Nat Rev Clin Oncol 7:153–162PubMedCentralPubMedCrossRef

19.

Bando H, Yoshino T, Tsuchihara K et al (2011) KRAS mutations detected by the amplification refractory mutation system––Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 105:403–406PubMedCentralPubMedCrossRef

20.

Watanabe T, Kobunai T, Yamamoto Y et al (2011) Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 47:1946–1954PubMedCrossRef

21.

George B, Kopetz S (2011) Predictive and prognostic markers in colorectal cancer. Curr Oncol Rep 13:206–215PubMedCrossRef

22.

Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257PubMedCentralPubMedCrossRef

23.

Kelley L, Silverstein M, Guerra L (2011) Analyzing the risk of recurrence after mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index. Ann Surg Oncol 18:459–462PubMedCrossRef

24.

Greenberg PL, Attar E, Bennett JM et al (2011) NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Cancer Netw 9:30–56

25.

Van Cutsem E, Oliveira J (2009) Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 20(Suppl 4):49–50PubMed

26.

Komatsu Y (2007) Adjuvant chemotherapy for colorectal cancer in Japan––current state and problem areas. Gan To Kagaku Ryoho 34:799–807PubMed

27.

Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466–474PubMedCrossRef

28.

Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261–1270PubMedCrossRef

29.

Deschoolmeester V, Boeckx C, Baay M et al (2010) KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer 103:1627–1636PubMedCentralPubMedCrossRef

30.

Kanemitsu M, Ueno H, Naito K et al (2012) A case of paraneoplastic limbic encephalitis associated with malignant lymphoma presenting with a late-onset bilateral thalamic lesion. Brain Nerve 64:71–77PubMed

31.

Bertagnolli MM, Redston M, Compton CC et al (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer—a study of CALGB 9581 and 89803. J Clin Oncol 29:3153–3162PubMedCentralPubMedCrossRef

32.

Elsaleh H, Joseph D, Grieu F et al (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745–1750PubMedCrossRef

33.

Bakin AV, Curran T (1999) Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science 283:387–390PubMedCrossRef

34.

Ordway JM, Williams K, Curran T (2004) Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene 23:3737–3748PubMedCrossRef

35.

van Engeland M, Derks S, Smits KM et al (2011) Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 29:1382–1391PubMedCrossRef

36.

Lievre A, Rouleau E, Buecher B, Mitry E (2010) Clinical significance of BRAF mutations in colorectal cancer. Bull Cancer 97:1441–1452PubMed

37.

Wong R, Cunningham D (2008) Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 26:5668–5670PubMedCrossRef

38.

Compton CC (1999) Pathology report in colon cancer: what is prognostically important? Dig Dis 17:67–79PubMedCrossRef

39.

Takeuchi K, Kuwano H, Tsuzuki Y et al (2004) Clinicopathological characteristics of poorly differentiated adenocarcinoma of the colon and rectum. Hepatogastroenterology 51:1698–1702PubMed

Title: Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer
Authors: Ryota Nakanishi
Jun Harada
Munkhbold Tuul
Yan Zhao
Koji Ando
Hiroshi Saeki
Eiji Oki
Takefumi Ohga
Hiroyuki Kitao
Yoshihiro Kakeji
Yoshihiko Maehara
Publication date: 01-12-2013
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-012-0501-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2013

Current chemotherapeutic approaches for hepatoblastoma

Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis

Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer

List of reviewers 2012–2013

Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia

Association between carotenoids and outcome of cervical intraepithelial neoplasia: a prospective cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer